Related Experiment Video
Updated: Nov 30, 2025

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
Infantile spasms: Etiology, lead time and treatment response in a resource limited setting
Priyanka Surana1,2, Joseph D Symonds2,3, Prabhar Srivastava1
1Departments' of Pediatrics, Pediatric Neurology & Radio Diagnosis, Santokba Durlabhji Memorial Hospital, Jaipur, India.
Insights
Timely treatment is crucial for infantile spasms (IS). Delays in initiating appropriate care, particularly in resource-limited settings, significantly worsen treatment outcomes and increase spasm resistance.
Area of Science:
- Neurology
- Pediatrics
- Genetics
Background:
- Infantile spasms (IS) are a severe epilepsy syndrome in infants.
- Etiology and treatment lead time significantly impact IS outcomes.
- Limited resource settings present unique challenges in managing IS.
Purpose of the Study:
- To explore the causes (etiology) of infantile spasms.
- To determine the time from IS onset to treatment initiation (lead time).
- To evaluate the impact of etiology and lead time on treatment responsiveness in a resource-limited setting.
Main Methods:
- Retrospective study of 113 IS patients with onset age ≤12 months.
- Patients categorized into Structural, Genetic, and Unknown etiological groups.
- Analysis of clinical data, neuroimaging, genetic results, and treatment response.
Main Results:
- Etiology was identified in 83.1% of patients; neonatal hypoglycemic brain injury (NHBI) was most common (36%).
- Structural etiology was associated with lower treatment resistance (p=0.013).
- A longer treatment lead time (median 60 days) significantly correlated with resistant spasms (p=0.0015).
Conclusions:
- NHBI is a primary cause of IS in this population.
- Significant delays in treatment initiation negatively affect spasm resolution.
- Optimizing early diagnosis and treatment is critical for improving outcomes in infantile spasms.
Abstract:
This study explores the etiology and lead time to treatment for infantile spasm (IS) patients and their effect on treatment responsiveness, in a limited resource setting. Patients with IS onset age ≤12 months', seen over 3 years were recruited retrospectively. Clinical information, neuroimaging and genetic results retrieved. Patients categorized into three primary etiological groups: Structural (including Structural Genetic), Genetic, and Unknown. The effect of etiology and lead time from IS onset to initiating appropriate treatment on spasm resolution, evaluated. Total 113 patients were eligible. Mean IS onset age was 6.86(±4.25) months (M: F 3.3:1). Patients were grouped into: Structural 85, Genetic 11 and Unknown 17. Etiology was ascertained in 94/113 (83.1%) with neonatal hypoglycemic brain injury (NHBI) being the most common (40/113, 36%). A genetic etiology identified in 17 (including 6 Structural Genetic, of which five had Tuberous Sclerosis). Structural group was less likely to be treatment resistant (p = 0.013, OR 0.30 [0.12-0.76]). Median treatment lead time - 60 days. Longer lead time to treatment was significantly associated with resistant spasms (χ2 for trend = 10.0, p = 0.0015). NHBI was the commonest underlying cause of IS. There was significant time lag to initiating appropriate treatment, affecting treatment responsiveness.
More Related Videos
Related Concept Videos
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Seizures: Classification
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Pharmacokinetics in Pediatric Patients: Drug Excretion

